THE RECOMBINANT 65-kD HEAT SHOCK PROTEIN OF MYCOBACTERIUM BOVIS BACILLUS CALMETTE-GUERIN/M. TUBERCULOSIS IS A TARGET MOLECULE FOR CD4+ CYTOTOXIC T LYMPHOCYTES THAT LYZE HUMAN MONOCYTES

By TOM H. M. OTTENHOFF,* BIRHANE KALE AB,* JAN D. A. VAN EMBDEN,† JELLE E. R. THOLE,* AND ROLF KIESSSLING*

From the *Armauer Hansen Research Institute, Addis Ababa, Ethiopia; and the †Laboratory of Bacteriology, National Institute of Public Health and Environmental Hygiene, Bilthoven, The Netherlands

Protective immunity against mycobacteria is dependent on antigen-specific Th lymphocytes. It has been assumed that these Th upon recognition of antigen/MHC secrete macrophage-activating factors that enable effector macrophages to eliminate the intracellular organism (1).

Recently, however, we have found that mycobacteria are very potent inducers of antigen-specific CD4+ and CD8+ cytotoxic T (Tc) cells as well as antigen-nonspecific killer cells that lyse human monocytes (2). Also, in experimental animal models, evidence has recently accumulated in favor of an important role for Tc cells in the immune response to mycobacteria (reviewed in reference 3). In addition, Mycobacterium bovis Bacillus Calmette-Guerin (BCG)-reactive human CD4+ T cell clones have been reported to lyse PPD-pulsed target (antigen-presenting) cells (4). The identification of the cytotoxic effector cells as well as the antigens that they recognize are of obvious importance for the design of mycobacterial subunit vaccines.

Here we report that the recombinant 65-kD heat shock protein (HSP) (5) of M. bovis BCG, which is identical to the 65-kD protein of M. tuberculosis, shares >95% sequence homology with the M. leprae 65-kD gene (6) and shows extensive crossreactivity with the latter (reference 7) is an immunodominant antigen for CD4+ BCG-specific Tc cells in a significant number (± 20%) of BCG-responsive individuals. In addition, recombinant 65-kD HSP-stimulated effector cells also efficiently lysed autologous monocytes in the absence of antigen. This observation may shed new light on the role of the 65-kD HSP in autoimmunity.

Materials and Methods

Lymphocyte Transformation Test (LTT). Ficoll-isolated PBMC of 58 mainly Ethiopian individuals were cultured with BCG, purified protein derivative (PPD) (both from Statens Serum Institute, Denmark) as a positive control and medium alone as a negative control. All cultures were performed in triplicate in 96-well U-bottom plates at a ratio of 107 PBMC per well. After incubation for 5 days at 37°C, the cultures were pulsed with 1 μCi of [3H]thymidine for the last 18 h. Cells were harvested on filter paper and their incorporated radioactivity was counted in a liquid scintillation counter. Results are expressed as mean cpm ± SE. A minimum of 46% specific incorporation was considered to be positive.

References

1. Ottenshoff THM, Kale AB, Van Embden JD, Thole JER, Keissling R (1988) Protective immunity against mycobacteria is dependent on antigen-specific Th lymphocytes. J Exp Med 168:1947-1952.

2. Ottenshoff THM, Kale AB, Van Embden JD, Thole JER, Keissling R (1988) Protective immunity against mycobacteria is dependent on antigen-specific Th lymphocytes. J Exp Med 168:1947-1952.
Inst., Denmark; 5 μg/ml), *M. leprae* (2.5 × 10⁷ bacilli/ml; provided by Dr. R. J. W. Rees, Mill Hill, UK), recombinant 65-kD HSP of BCG (5 μg/ml), or control RPMI 1640 + 5% normal human serum, pulsed on day 6 with [³H]thymidine, harvested 18 h later, and counted by liquid scintillation counting (Rackbeta II; LKB Instruments, Inc., Gaithersburg, MD).

**Cytotoxicity Assay.** As described in detail in reference 2, PBMC were stimulated during 7 d with PPD, BCG, or the recombinant 65-kD HSP of BCG in 24-well tissue culture plates (Linbro; Flow Laboratories, McLean, VA) (10⁶ cells/ml).

Target cells were day 6 adherent cells of PBMC that had been plated in 96-well U-bottomed tissue culture plates (1.5 × 10⁵ cells/well) (Titertek; Flow Laboratories). Approximately 10% of the cells adhered. This number was used for calculating E/T ratios. On day 6, the cells were pulsed with antigen (PPD, 25 μg/ml; BCG, 25 μg/ml; tetanus toxoid, 1:120 dilution; recombinant 65-kD HSP of BCG, 20 μg/ml) and labeled with 2 μCi of 51 sodium chromate (Amersham International, Amersham, UK) during 18 h and then washed three times with preheated medium. Effector cells were then added in triplicate to the target cells (150 μl/well). One triplicate with medium only was used for the determination of spontaneous release. 15 h later the total supernatant content of each well was transferred to a detachable counting tube (Linbro; Flow Laboratories) and 100 μl of triton-X was added to the original wells to lyse the remaining adherent cells. After 3 h the total volume of triton-X was transferred to similar tubes and the samples were counted (1270 Rack Gamma; LKB Instruments, Inc.). The percentage-specific killing for each individual well was calculated as follows: percent specific lysis = [test cpm/(test cpm + cpm after triton-X treatment of the same well)] × 100% – percent spontaneous release. The percentage spontaneous release was calculated as follows: cpm in spontaneous release well/(cpm in spontaneous release well + cpm after triton-X treatment of the same well) × 100%.

**Depletion of Lymphocyte Subsets with mAb-coated Magnetic Beads.** Magnetic beads (Dynal A. S., Oslo, Norway) were coated with rabbit anti-mouse Ig (Dakopatts, Glostrup, Denmark) and then incubated with 50 μl of the appropriate second layer mAb (Leu-1 (CD5), Leu-2 (CD8), Leu-19 (HNK-1) (all from Becton Dickinson & Co., Mountain View, CA), BMA 044 (CD4) (Behringwerke AG, Marburg, Federal Republic of Germany) or normal mouse serum [control beads]). Cells and beads were mixed in a 1:4 ratio, centrifuged for 5 min at 4°C (1,000 rpm), and then incubated for another 15 min on ice. The pellet was gently resuspended and depleted for marker-positive cells with a magnetic particle concentrator (Dynal A. S.). The procedure was repeated two more times. Control bead-depleted cells were resuspended in complete medium to give a 30:1 E/T ratio in the highest concentration. The other cell suspensions were resuspended in the same volume as the control bead-depleted cells. Depletion was usually 85–100% effective as determined by immunofluorescence.

**Results**

**Proliferative PBMC Responses of BCG Responder Individuals to the Recombinant 65-kD HSP of BCG.** PBMC of 47 out of 58 individuals proliferated (i.e., >5,000 cpm) to BCG. Nine individuals (19%) also responded to the recombinant 65-kD purified HSP of BCG (Table I).

The recombinant 65-kD HSP of BCG is an immunodominant target molecule for PPD/BCG-induced cytotoxic effector cells that specifically lyse antigen-pulsed monocytes. PPD- or BCG-stimulated effector cells from recombinant 65-kD responsive donors efficiently lysed PPD-pulsed, and to a much lower extent, nonpulsed or tetanus toxoid-pulsed autologous monocyte targets in a dose-dependent manner (Table II). PPD-induced effector cells of recombinant 65-kD (LTT) responsive donors also lysed recombinant 65-D-pulsed monocytes as efficiently as PPD-pulsed ones. PPD-stimulated effector cells of a recombinant 65-kD LTT nonresponder lysed PPD-pulsed but not recombinant 65-kD-pulsed monocytes (Table II, Exp. #). The recombinant 65-kD HSP of BCG, therefore, appears to be an important target molecule for PPD- or BCG-stimulated cytotoxic effector cells of recombinant 65-kD LTT-responsive but non-responsive donors.
Table I

Proliferative Responses of PBMC from Different Individuals to M. bovis BCG, M. leprae, and the Recombinant 65-kD HSP of BCG Protein

| No. | Clinical diagnosis | BCG/PPD | Recombinant 65-kD protein | M. leprae | Control |
|-----|-------------------|---------|---------------------------|----------|--------|
| 1   | Normal            | 145,204 ± 8,733 | 53,710 ± 1,989 | 51,493 ± 4,797 | 821 ± 607 |
| 2   | Normal            | 162,243 ± 19,893 | 12,229 ± 3,674 | 66,261 ± 6,333 | 2,208 ± 306 |
| 3   | Normal            | 60,607 ± 11,584 | 9,898 ± 3,497 | 19,507 ± 2,381 | 540 ± 122 |
| 4   | Normal            | 172,745 ± 14,839 | 20,585 ± 5,305 | ND        | 1,116 ± 453 |
| 5   | Normal            | 140,741 ± 4,314 | 5,906 ± 6 | 8,093 ± 2,955 | 1,633 ± 466 |
| 6   | BT                | 55,735 ± 7,758 | 10,504 ± 2,011 | 56,140 ± 11,884 | 2,369 ± 812 |
| 7   | BT                | 61,246 ± 11,991 | 5,796 ± 508 | 56,211 ± 4,057 | 1,834 ± 811 |
| 8   | BT                | 53,524 ± 22,286 | 22,535 ± 3,286 | 5,807 ± 1,264 | 2,863 ± 851 |
| 9   | LL                | 59,357 ± 12,137 | 21,901 ± 5,175 | 955 ± 98 | 1,202 ± 224 |

The results are expressed as mean cpm ± SEM of [3H]thymidine incorporation by triplicate cultures of 2 x 10^5 PBMC each. Results are only shown for the 9 out of 47 (21 healthy contacts, 13 BT, and 13 LL patients) BCG responsive individuals that responded to the recombinant 65-kD protein (see Materials and Methods).

* BT, borderline tuberculoid leprosy.
† LL, lepromatous leprosy.

The Recombinant 65-kD HSP of BCG is an Immunodominant Stimulatory Molecule for Cytotoxic Effector Cells that Lysed both PPD and Recombinant 65-kD HSP of BCG-pulsed Monocytes. To investigate if the recombinant 65-kD HSP of BCG also was immunodominant at the precursor rather than at the effector level, we raised recombinant 65-kD-stimulated effector cells from LTT-responsive donors. These effector cells efficiently lysed recombinant 65-kD-pulsed monocytes and, importantly, also PPD-pulsed monocytes (Table II). Nonpulsed or irrelevant antigen-pulsed monocytes were lysed to a lower extent than PPD- or recombinant 65-kD-pulsed ones, but recombinant 65-kD-induced effector cells lysed nonpulsed monocytes much more (roughly twice as) efficiently than did PPD- or BCG-induced cytotoxic cells.

The recombinant 65-kD HSP of BCG thus is an efficient stimulatory molecule for precursors of cytotoxic effector cells that specifically lyse PPD- and recombinant 65-kD-pulsed monocytes but also strongly lyse monocytes in the absence of antigen.

Membrane Phenotype of PPD and Recombinant 65-kD HSP of BCG-induced Cytotoxic Effector Cells. PPD or recombinant 65-kD HSP of BCG-induced effector cells predominantly consisted of CD3+/CD5+/CD4+ T cells (data not shown). The depletion of CD4 but not CD8 or Leu-19+ cells from the effector population reduced or abrogated lytic activity against both PPD and recombinant 65-kD protein-pulsed monocytes (Fig. 1).

Discussion

The 65-kD HSP is a major immunogenic component of M. bovis BCG, M. tuberculosis, and M. leprae, and is frequently recognized by murine and human B cells and helper T cells (6–8). Little is known about the possible role of Tc cells in the human immune response to mycobacteria. We here show that the 65-kD HSP of M. bovis BCG/M. tuberculosis is an immunodominant target molecule for BCG/PPD-specific CD4+ Tc lymphocytes that lyse human monocytes, and is an immunodominant...
Antigen-specific and Antigen-nonspecific Lysis of Monocyte Targets by BCG/PPD or Recombinant 65-kD HSP of BCG-stimulated Cytotoxic Effector Lymphocytes

| Exp | Individual | Stimulating antigen | LTT index* | E/T ratio | PPD   | HSP   | BCG | Recombinant 65-kD HSP | Tetao toxoid | No antigen |
|-----|------------|---------------------|------------|-----------|-------|-------|-----|----------------------|--------------|------------|
| 1   | 1          | BCG                 | 177        | 50:1      | 52    | 52    | ND  | 19                   |              |            |
|     |            |                     |            | 15:1      | 53    | 43    | ND  | 11                   |              |            |
|     |            |                     |            | 5:1       | 44    | 35    | ND  | 11                   |              |            |
|     |            | Recombinant 65-kD   | 65         | 40:1      | ND    | 58    | ND  | 41                   |              |            |
|     |            | 65-kD BCG           |            | 12:1      | ND    | 53    | ND  | 37                   |              |            |
|     |            |                     |            | 4:1       | ND    | 40    | ND  | 14                   |              |            |
| 2   | 2          | PPD                 | 112        | 40:1      | 69    | 62    | ND  | 29                   |              |            |
|     |            |                     |            | 12:1      | 67    | 58    | ND  | 22                   |              |            |
|     |            |                     |            | 4:1       | 57    | 52    | ND  | 14                   |              |            |
|     |            | Recombinant 65-kD   | 18         | 40:1      | 50    | 63    | ND  | 41                   |              |            |
|     |            | 65-kD BCG           |            | 12:1      | 60    | 61    | ND  | 35                   |              |            |
|     |            |                     |            | 4:1       | 56    | 57    | ND  | 25                   |              |            |
| 3   | 3          | PPD                 | 155        | 50:1      | 45    | 29    | 21  | 20                   |              |            |
|     |            |                     |            | 15:1      | 57    | 22    | 19  | 12                   |              |            |
|     |            |                     |            | 5:1       | 38    | 16    | 0   | 5                    |              |            |
|     |            | Recombinant 65-kD   | 18         | 25:1      | 33    | 37    | 23  | 20                   |              |            |
|     |            | 65-kD BCG           |            | 8:1       | 19    | 26    | 12  | 10                   |              |            |
|     |            |                     |            | 2:1       | 9     | 10    | 2   | 1                    |              |            |
| 4   | 4          | PPD                 | 19/41      | 50:1      | 54    | 5     | 21  | 17                   |              |            |
|     |            |                     |            | 9:1       | 38    | 0     | 12  | 7                    |              |            |
|     |            |                     |            | 3:1       | 25    | 0     | 7   | 3                    |              |            |

Results are expressed as the mean percentage specific lysis of triplicate cultures calculated as described in Materials and Methods. SEM were mostly <10%.

* LTT index, cpm in antigen-stimulated cultures/cpm in nonstimulated cultures.

† LTT index for the recombinant 65-kD HSP of BCG.

In mice, Tc cells are an important component of the immune response to mycobacteria (3). We have recently found that in humans, as well, mycobacteria are very potent inducers of antigen-specific CTL that lyse monocytes (2) and that these effector cells, in parallel with lysing infected target cells, also kill intracellularly located live mycobacteria (Kumararatne, D. S., B. Kale Ab, R. Kiessling, P. Converse, and T. Ottenhoff, unpublished results). This suggests that Tc cells may be pivotal effector cells in the actual protection against mycobacterial infections. The fact that the recombinant 65-kD HSP of BCG expresses immunodominant epitopes for peripheral Tc cells (this study) as well as B cells (6, 7) and Th (6-8) in a significant number of individuals renders this protein a seemingly interesting candidate for subunit vaccines.

The recombinant 65-kD HSP of BCG was only immunodominant in ±20% of the individuals tested and we are presently trying to define the antigens of BCG...
that can induce cytotoxic cells in those BCG responders that do not respond to the recombinant 65-kD HSP.

An interesting observation was the remarkably high level of killing of autologous nonpulsed monocytes by recombinant 65-kD-induced cytotoxic cells. The former effector cells also strongly expressed the Leu-19 (HNK-1) marker as well as strong lytic activity against tumor cell lines (unpublished observations). An important and clinically relevant side effect of an immune response primarily focussed to the recombinant 65-kD HSP might thus be self (specific or nonspecific) reactivity that could result in tissue destruction, an essential feature of tuberculosis and tuberculoid leprosy. Several other studies support a pathological role for the recombinant 65-kD HSP: adjuvant arthritis can be induced in Lewis rats by recombinant 65-kD HSP-reactive T cell clones (9). T cells from rheumatoid arthritis patients recognize an M. tuberculosis fraction (10) that is probably enriched for the recombinant 65-kD HSP. T cell clones from tuberculoid (high responder) leprosy patients also frequently recognize the same HSP (7).

Future studies will have to determine whether the 65-kD determinants that are recognized by protective Tc cells and Th can be dissociated from the determinants that induce autoreactive T cell and non-T cell cytotoxic effector cells.

Summary

Since little is known about Tc cells in the human immune response to intracellular parasites, we have studied the role of Tc cells in response to M. bovis Bacillus Calmette-Guerin (BCG). Donors whose PBMC responded to BCG, purified protein derivative (PPD), and the recombinant 65-kD heat shock protein (HSP) of BCG gener-
ated BCG/PPD-specific CD4+ effector T lymphocytes that lysed PPD as well as recombinant 65-kD-pulsed monocytes. Nonpulsed or irrelevant antigen-pulsed target cells were lysed to a much lower but still significant extent. PPD-stimulated effector lymphocytes of a recombinant 65-kD nonresponder lysed PPD but not recombinant 65-kD-pulsed monocytes.

Recombinant 65-kD-educated effector lymphocytes lysed both recombinant 65-kD- and PPD-pulsed monocytes. In addition, these effector cells efficiently lysed nonpulsed target cells. These results demonstrate that in recombinant 65-kD responders, the recombinant 65-kD HSP of BCG is an immunodominant target as well as a triggering molecule for BCG/PPD-specific CD4+ cytotoxic T cells that lyse autologous monocytes. The implications of these findings with respect to the role of the 65-kD HSP in autoimmunity are discussed.

We thank the ALERT doctors, and Mrs. Asrat Tilahun and Mrs. Mulunesh Negash for their help.

Received for publication 16 June 1988 and in revised form 1 August 1988.

References

1. Hahn, H., and S. H. E. Kaufmann. 1981. The role of cell-mediated immunity in bacterial infections. Rev. Infect. Dis. 3:1221.

2. Birhane Kaleab, R. Kiessling, M. Rottenberg, P. Converse, G. Tadesse, and T. Ottenhoff. BCG and Mycobacterium leprae induce antigen specific CD4 and CD8 HLA restricted cytotoxic T cells as well as antigen nonspecific HLA unrestricted killer cells that lyse human macrophages. Submitted for publication.

3. Kaufmann, S. H. E. 1988. CD8+ T lymphocytes in intracellular microbial infections. Immunol. Today. 9:168.

4. Mustafa, A. S., and T. Godal. 1987. BCG induced CD4+ cytotoxic T cells from BCG vaccinated healthy subjects: relation between cytotoxicity and suppression in vitro. Clin. Exp. Immunol. 69:255.

5. Shinnick, T. M., M. H. Vodkin, and J. C. Williams. 1988. The Mycobacterium tuberculosis 65-Kilodalton antigen is a heat shock protein which corresponds to common antigen and to the Escherichia coli GroEl protein. Infect. Immun. 56:446.

6. Young, D. B., J. Ivanji, J. H. Cox, and J. R. Lamb. 1987. The 65kD antigen of mycobacteria, a common bacterial protein? Immunol. Today. 8:215.

7. Thole, J. E. R., W. G. A. van Schooten, W. J. Keulen, P. W. M. Hermans, A. A. M. Janson, R. R. P. de Vries, A. H. J. Kolk, and J. D. A. van Embden. 1988. Use of recombinant antigens expressed in Escherichia coli K-12 to map B cell and T cell epitopes on the immunodominant 65 kilodalton protein of Mycobacterium bovis BCG. Infect. Immun. 56:1633.

8. Emmrich, F., J. Thole, J. van Embden, and S. H. E. Kaufmann. 1986. A recombinant 64-kilodalton protein of Mycobacterium bovis Bacillus Calmette-Guerin specifically stimulates human T4 clones reactive to mycobacterial antigens. J. Exp. Med. 163:1024.

9. Van Eden, W., J. E. R. Thole, R. van der Zee, A. Noordzy, J. D. A. van Embden, E. J. Hensen, and I. R. Cohen. 1988. Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis. Nature (Lond.). 331:171.

10. Holoshitz, J., A. Klajman, I. Drucker, Z. Lapidot, A. Yaretzky, A. Frenkel, W. van Eden, and I. R. Cohen. 1986. T lymphocytes from rheumatoid arthritis patients show augmented reactivity to a fraction of mycobacteria cross-reactive with cartilage. Lancet ii:305.